Tactiva Therapeutics is pioneering advanced adoptive cell therapy (ACT) strategies aimed at delivering targeted and effective treatments for cancer. Their innovative approach involves reprogramming patients' own T cells, specifically focusing on both CD8 and CD4 T cell receptors (TCRs). By utilizing a unique library of TCRs, Tactiva enhances the anti-tumor response, allowing CD4 T cells to not only support the function of CD8 T cells but also directly attack cancer cells. This dual approach aims to create a robust and sustained immune response against tumors, leading to improved patient outcomes and potential long-term remission.

In addition to employing mature T cells, Tactiva's platform incorporates the use of hematopoietic stem cells (HSCs) that are genetically modified to express the TCRs. As these stem cells mature within the patient, they provide a continuous source of cancer-fighting T cells, ensuring ongoing immune surveillance and attack against tumors. This synergistic strategy, which combines the cytotoxic capabilities of both CD4 and CD8 TCRs, is designed to effectively target solid tumors expressing specific antigens, such as NY-ESO-1, thereby enhancing the overall efficacy of the treatment and offering hope for durable cancer remission.

United States

Tactiva Therapeutics is an immuno-oncology company specializing in potent cancer immunotherapy using a dual T cell receptor approach.

Tactiva Therapeutics

Company Details